ES2349416T3 - Tienopiridinas como potenciadores alostéricos del receptor muscarínico m4. - Google Patents

Tienopiridinas como potenciadores alostéricos del receptor muscarínico m4. Download PDF

Info

Publication number
ES2349416T3
ES2349416T3 ES05812144T ES05812144T ES2349416T3 ES 2349416 T3 ES2349416 T3 ES 2349416T3 ES 05812144 T ES05812144 T ES 05812144T ES 05812144 T ES05812144 T ES 05812144T ES 2349416 T3 ES2349416 T3 ES 2349416T3
Authority
ES
Spain
Prior art keywords
compound
mmol
methyl
chloro
amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05812144T
Other languages
English (en)
Spanish (es)
Inventor
Almudena Rubio Esteban
Darryl Wayne Hilliard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2349416T3 publication Critical patent/ES2349416T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Medicinal Chemistry (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Measurement Of Velocity Or Position Using Acoustic Or Ultrasonic Waves (AREA)
ES05812144T 2004-10-25 2005-10-18 Tienopiridinas como potenciadores alostéricos del receptor muscarínico m4. Expired - Lifetime ES2349416T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62178504P 2004-10-25 2004-10-25
US621785P 2004-10-25

Publications (1)

Publication Number Publication Date
ES2349416T3 true ES2349416T3 (es) 2011-01-03

Family

ID=36021809

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05812144T Expired - Lifetime ES2349416T3 (es) 2004-10-25 2005-10-18 Tienopiridinas como potenciadores alostéricos del receptor muscarínico m4.

Country Status (16)

Country Link
US (1) US8071776B2 (enExample)
EP (1) EP1807434B1 (enExample)
JP (1) JP4945453B2 (enExample)
CN (1) CN100577666C (enExample)
AT (1) ATE478876T1 (enExample)
AU (1) AU2005299957B2 (enExample)
BR (1) BRPI0517438A (enExample)
CA (1) CA2583550C (enExample)
CY (1) CY1111477T1 (enExample)
DE (1) DE602005023197D1 (enExample)
DK (1) DK1807434T3 (enExample)
ES (1) ES2349416T3 (enExample)
MX (1) MX2007004794A (enExample)
PL (1) PL1807434T3 (enExample)
PT (1) PT1807434E (enExample)
WO (1) WO2006047124A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013126856A1 (en) * 2012-02-23 2013-08-29 Vanderbilt University Substituted 5-aminothieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
WO2014035829A1 (en) * 2012-08-31 2014-03-06 Vanderbilt University Substituted 3-aminothieno[2,3-c]pyridine-2-carboxamide analogs as positive allosteric modulators
US9908893B2 (en) 2013-06-11 2018-03-06 Latvian Institute Of Organic Synthesis Thieno [2,3-b] pyridines as multidrug resistance modulators
EP3036233A1 (en) 2013-08-23 2016-06-29 Vanderbilt University Substituted thieno[2,3-c]pyridazine-6-carboxamide analogs as positive allosteric modulators of the muscarinic acetylcholine receptor m4
ES2789756T3 (es) 2015-12-23 2020-10-26 Merck Sharp & Dohme Moduladores alostéricos de 6,7-dihidro-5H-pirrolo[3,4-b]piridin-5-ona del receptor de acetilcolina muscarínico M4
WO2017107089A1 (en) 2015-12-23 2017-06-29 Merck Sharp & Dohme Corp. 3- (1h-pyrazol-4-yl) pyridineallosteric modulators of the m4 muscarinic acetylcholine receptor
KR102474326B1 (ko) 2016-06-22 2022-12-05 반더빌트유니버시티 무스카린성 아세틸콜린 수용체 m4의 양성 알로스테릭 조절제
SG11201811712QA (en) 2016-07-01 2019-01-30 Pfizer 5,7-dihydro-pyrrolo-pyridine derivatives for treating neurological and neurodegenerative diseases
GB201616839D0 (en) 2016-10-04 2016-11-16 Takeda Pharmaceutical Company Limited Therapeutic compounds
US11008335B2 (en) 2016-11-07 2021-05-18 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor M4
EP3558309B1 (en) 2016-11-07 2023-07-26 Vanderbilt University Positive allosteric modulators of the muscarinic acetylcholine receptor m4
ES2892956T3 (es) 2016-11-07 2022-02-07 Univ Vanderbilt Moduladores alostéricos positivos del receptor muscarínico de acetilcolina M4
WO2018112840A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6, 5-fused heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
WO2018112842A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. 6,6-fused heteroaryl piperidine ether allosteric modulators of m4 muscarinic acetylcholine receptor
WO2018112843A1 (en) 2016-12-22 2018-06-28 Merck Sharp & Dohme Corp. Heteroaryl piperidine ether allosteric modulators of the m4 muscarinic acetylcholine receptor
FI3642202T3 (fi) 2017-06-22 2023-03-01 Dihydro-pyrrolo-pyridiinijohdannaisia
WO2019000237A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000238A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. 5- (PYRIDIN-3-YL) OXAZOLE ALLOSTERIC MODULATORS OF M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
WO2019000236A1 (en) 2017-06-27 2019-01-03 Merck Sharp & Dohme Corp. ALLOSTERIC MODULATORS OF 3- (1H-PYRAZOL-4-YL) PYRIDINE FROM THE M4 ACETYLCHOLINE MUSCARINIC RECEPTOR
TW201930311A (zh) 2017-12-05 2019-08-01 泛德比爾特大學 蕈毒鹼型乙醯膽鹼受體m4之正向別構調節劑
CN111406058A (zh) 2017-12-05 2020-07-10 范德比尔特大学 毒蕈碱型乙酰胆碱受体m4的正向别构调节剂
WO2025201078A1 (zh) * 2024-03-25 2025-10-02 四川科伦药物研究院有限公司 化合物、包含其的药物组合物及其制备方法和用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3430284A1 (de) * 1984-08-17 1986-02-27 Troponwerke GmbH & Co KG, 5000 Köln Neue tryptamin-derivate, ein verfahren zu ihrer herstellung und ihre verwendung
NZ290199A (en) * 1994-07-27 1999-06-29 Sankyo Co Nitrogen containing heterocyclic compounds, selective allosteric effectors to regulate m1 receptors
US6841684B2 (en) * 1997-12-04 2005-01-11 Allergan, Inc. Imidiazoles having reduced side effects
GB9924962D0 (en) * 1999-10-21 1999-12-22 Mrc Collaborative Centre Allosteric sites on muscarinic receptors
CN1814596A (zh) * 2000-04-28 2006-08-09 阿卡蒂亚药品公司 毒蕈碱性激动剂
MXPA04007083A (es) * 2002-02-20 2004-10-29 Upjohn Co Compuestos azabiciclicos para el tratamiento de enfermedades.
US6974870B2 (en) * 2002-06-06 2005-12-13 Boehringer Ingelheim Phamaceuticals, Inc. Substituted 3-amino-thieno [2,3-b]pyridine-2-carboxylic acid amide compounds and processes for preparing and their uses

Also Published As

Publication number Publication date
DE602005023197D1 (de) 2010-10-07
AU2005299957B2 (en) 2011-04-21
JP2008517913A (ja) 2008-05-29
CN101048413A (zh) 2007-10-03
AU2005299957A1 (en) 2006-05-04
DK1807434T3 (da) 2010-11-22
MX2007004794A (es) 2007-07-09
US8071776B2 (en) 2011-12-06
CY1111477T1 (el) 2015-08-05
CA2583550A1 (en) 2006-05-04
PT1807434E (pt) 2010-09-22
CN100577666C (zh) 2010-01-06
EP1807434A1 (en) 2007-07-18
JP4945453B2 (ja) 2012-06-06
WO2006047124A1 (en) 2006-05-04
PL1807434T3 (pl) 2011-02-28
CA2583550C (en) 2013-05-14
US20090105244A1 (en) 2009-04-23
EP1807434B1 (en) 2010-08-25
ATE478876T1 (de) 2010-09-15
BRPI0517438A (pt) 2008-10-07

Similar Documents

Publication Publication Date Title
ES2349416T3 (es) Tienopiridinas como potenciadores alostéricos del receptor muscarínico m4.
ES2233671T3 (es) Derivados de benzimidazol, su preparacion y aplicacion en terapeutica.
ES2442369T3 (es) Derivados de quinolina y quinoxalina como inhibidores de cinasa
ES2416364T3 (es) Derivados de tiazol condensados como inhibidores de cinasas
ES2430663T3 (es) Compuestos heterocíclicos para el tratamiento de afecciones relacionadas con el estrés
WO2023280280A1 (zh) 作为KRas G12D抑制剂的稠环化合物
BR112021011643A2 (pt) Compostos macrocíclicos e seu uso no tratamento de doença
CA3031073A1 (en) N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease
KR100823414B1 (ko) 카르보스티릴 화합물
ES2648512T3 (es) Derivados de carbamato/urea
BR112013021566B1 (pt) composto, composição farmacêutica e uso de um composto de fórmula (i)
ES2340772T3 (es) Nuevas formas cristalinas (2-(1-(3,5-bis-trifluorometilbencil)-5-piridin-4-il-1h-(1,2,3)triazol-4-il)-piridin-3-il)-(2-clorofenil)-metadona.
JP2019526577A (ja) イミダゾール誘導体及び自己免疫性疾患若しくは炎症性疾患又は癌の治療におけるそれらの使用
ES2309398T3 (es) Derivados 3,4-dihidro-tieno (2,3-d)pirimidin-4-ona-3-sustituidos, produccion y sus usos.
JPH06116237A (ja) 〔（アリールアルキルピペリジン−４−イル）メチル〕−２ａ，３，４，５−テトラヒドロ−１（２Ｈ）−アセナフチレン−１−オン類および関連化合物
CA2623154A1 (en) Novel fused pyrrole derivative
AU2002325493B2 (en) Condensed Polycyclic Compounds
WO2022174765A1 (zh) 作为Wee-1抑制剂的稠环化合物
ES2405055T3 (es) Agonistas muscarínicos
BRPI0813777B1 (pt) composto, composição farmacêutica, e, uso de um composto
US20100317630A1 (en) Novel heterocyclic compounds as mglu5 antagonists
TW201139432A (en) Monomaleate of benzothiazine compound
CN114945368B (zh) N2-芳基甲基-4-卤代烷基-哒嗪-3-酮化合物及其用途
ES2936077T3 (es) Método para producir un derivado de piridona policíclico sustituido y un cristal del mismo
TW201136938A (en) Spiropiperidine benzylamines as beta-tryptase inhibitors